Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Melioidosis Vaccine Development Workshop

Friday, March 21, 2014 - Friday, March 21, 2014
Porton Down, Salisbury, England

The primary goal of the MVDC is to accelerate research toward and development of a melioidosis vaccine, with secondary goals of enabling basic and applied research in fundamental and translational melioidosis research. The committee will recommend a development pathway, considering both therapeutic and prophylactic vaccines. The role of a therapeutic vaccine will be to decrease the duration of an onerous antibiotic regimen, and also to provide a critical time-frame to treat patients with secondary causes of mortality from the disease, such as diabetes. These activities will provide the framework for collaborations among NIH-funded researchers and other international scientists in the field and advance the field in the most important, cutting edge directions.

Suman Mukhopadhyay, Ph.D., (301) 451-3032

Co-funding Institute(s):
National Institute of Allergy and Infectious Diseases
Office of Rare Diseases Research

From the National Center for Advancing Translational Sciences

From the National Institutes of Health

Connect with ORDR

See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.